Literature DB >> 23214195

Evaluation of the effects of a high dose of erythropoietin-beta on early endotoxemia using a rat model.

Zehra Eren1, Jale Coban, Işin D Ekinci, Cigdem Kaspar, Gülçlin Kantarci.   

Abstract

BACKGROUND: Endotoxins can cause serious organ damage and death by triggering the secretion of pro-inflammatory cytokines such as TNF-alpha, IL-6 and IL-1beta in bacterial infections.
OBJECTIVES: The goal of this study was to evaluate the effects of a high dose (3000 U/kg) of erythropoietin-beta (EPO) on inflammatory cytokine levels, renal function and histological changes during the early period of Lipopolysaccharide (LPS)-induced endotoxemia using a rat model.
MATERIAL AND METHODS: Male Sprague Dawley (350-400 g) rats were randomized into 3 groups: Control group (n = 7); LPS group (received 20 mcg/kg LPS through intraperitoneal (i.p.) injection (n = 7); LPS+EPO group (received 3000 U/kg, ip 30 minutes before LPS administration (n = 7). Four hours after the administration of LPS, kidney tissue and serum samples were collected. Kidney function parameters, TNF-alpha, IL-6, IL-1beta, C reactive protein (CRP) and complete blood counts (CBC) were measured. The severity of renal tubular injury and caspase-9 immunoreactive cells was expressed as a percentage.
RESULTS: Serum levels of urea, creatinine, TNF-alpha, IL-6 and IL-1beta were significantly increased in the LPS group (p < 0.0001 - p = 0.04) and were lower in LPS+EPO group (p < 0.0001, p = 0.01, p = 0.02, p = 01 and p < 0.0001, respectively). Pretreatment with EPO significantly increased platelet counts (p = 0.00) and decreased white blood cell counts (p = 0.02). The renal tubular injury percentage was significantly higher in the LPS group than in the control and LPS+EPO groups (p = 0.002, p = 0.003, and p = 0.005, respectively) and caspase-9 expression was lower in the LPS+EPO and control groups than in the LPS group.
CONCLUSIONS: EPO might have renoprotective effects against the inflammatory process and cell apoptosis during endotoxemia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23214195

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  4 in total

1.  Endogenous erythropoietin varies significantly with inflammation-related proteins in extremely premature newborns.

Authors:  J Wells Logan; Elizabeth N Allred; Raina N Fichorova; Stephen Engelke; Olaf Dammann; Alan Leviton
Journal:  Cytokine       Date:  2014-06-02       Impact factor: 3.861

Review 2.  Bridging Translation by Improving Preclinical Study Design in AKI.

Authors:  Mark de Caestecker; Ben D Humphreys; Kathleen D Liu; William H Fissell; Jorge Cerda; Thomas D Nolin; David Askenazi; Girish Mour; Frank E Harrell; Nick Pullen; Mark D Okusa; Sarah Faubel
Journal:  J Am Soc Nephrol       Date:  2015-11-04       Impact factor: 10.121

3.  Effect of erythropoietin loading chitosan-tripolyphosphate nanoparticles on an IgA nephropathy rat model.

Authors:  Xiaoli Zhang; Yin Wu; Kun Sun; Jing Tan
Journal:  Exp Ther Med       Date:  2014-03-28       Impact factor: 2.447

4.  Erythropoietin Combined with Liposomal Amphotericin B Improves Outcome during Disseminated Aspergillosis in Mice.

Authors:  Nathalie Rousseau; Stephane Picot; Anne-Lise Bienvenu
Journal:  Front Immunol       Date:  2014-10-14       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.